{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:31Z","timestamp":1790270731756,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00296-011-2032-6","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T11:24:27Z","timestamp":1311593067000},"page":"2561-2563","source":"Crossref","is-referenced-by-count":11,"title":["Coexistence of primary aldosteronism and Hashimoto\u2019s thyroiditis"],"prefix":"10.1007","volume":"32","author":[{"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Okopien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"2032_CR1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MED.0b013e3283390f8d","volume":"17","author":"P Mulatero","year":"2010","unstructured":"Mulatero P, Monticone S, Bertello C, Tizzani D, Iannaccone A, Crudo V, Veglio F (2010) Evaluation of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 17:188\u2013193","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2032_CR2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"W Young","year":"2007","unstructured":"Young W (2007) Primary aldosteronism: renaissance of the syndrome. Clin Endocrinol 66:607\u2013618","journal-title":"Clin Endocrinol"},{"key":"2032_CR3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1507\/endocrj.KR-80","volume":"54","author":"T Yoshimoto","year":"2007","unstructured":"Yoshimoto T, Hirata Y (2007) Aldosterone as a cardiovascular risk hormone. Endocr J 54:359\u2013370","journal-title":"Endocr J"},{"key":"2032_CR4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/BOR.0b013e3280113d1a","volume":"19","author":"P Caturegli","year":"2007","unstructured":"Caturegli P, Kimura H, Rocchi R, Rose NR (2007) Autoimmune thyroid diseases. Curr Opin Rheumatol 19:44\u201348","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 2","key":"2032_CR5","first-page":"205","volume":"1","author":"R Lorini","year":"2003","unstructured":"Lorini R, Gastaldi R, Traggiai C, Perucchin PP (2003) Hashimoto\u2019s thyroiditis. Pediatr Endocrinol Rev 1(Suppl 2):205\u2013211","journal-title":"Pediatr Endocrinol Rev"},{"key":"2032_CR6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2169\/internalmedicine.41.967","volume":"41","author":"M Tanaka","year":"2002","unstructured":"Tanaka M, Izeki M, Miyazaki Y, Horigome M, Yoneda T, Tsuyuki S, Takami S, Aiba M (2002) Combined primary aldosteronism and Cushing\u2019s syndrome due to a single adrenocortical adenoma complicated by Hashimoto\u2019s thyroiditis. Intern Med Nov 41:967\u2013971","journal-title":"Intern Med Nov"},{"key":"2032_CR7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.fjc.0000175455.46245.c8","volume":"46","author":"B Okopie\u0144","year":"2005","unstructured":"Okopie\u0144 B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieli\u0144ski M, Herman ZS (2005) Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 46:377\u2013386","journal-title":"J Cardiovasc Pharmacol"},{"key":"2032_CR8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.atherosclerosis.2004.05.009","volume":"176","author":"B Okopie\u0144","year":"2004","unstructured":"Okopie\u0144 B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieli\u0144ski M, Labuzek K, Herman ZS (2004) The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176:327\u2013335","journal-title":"Atherosclerosis"},{"key":"2032_CR9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MOP.0b013e32832cf824","volume":"21","author":"RS Brown","year":"2009","unstructured":"Brown RS (2009) Autoimmune thyroid disease: unlocking a complex puzzle. Curr Opin Pediatr 21:523\u2013528","journal-title":"Curr Opin Pediatr"},{"key":"2032_CR10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2249.2003.02249.x","volume":"134","author":"K Bendtzen","year":"2003","unstructured":"Bendtzen K, Hansen PR, Rieneck K, Spironolactone\/Arthritis Study Group (2003) Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 134:151\u2013158","journal-title":"Clin Exp Immunol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00296-011-2032-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T05:10:18Z","timestamp":1560402618000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-011-2032-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["2032"],"URL":"https:\/\/doi.org\/10.1007\/s00296-011-2032-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]}}}